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Abstract
Purpose—To identify a profile of circulating tumor HPV DNA (ctHPVDNA) clearance kinetics 
that is associated with disease control after chemoradiotherapy (CRT) for HPV-associated 
oropharyngeal squamous cell carcinoma (OPSCC).
Patients and methods—A multi-institutional prospective biomarker trial was conducted in 103 
patients with: 1) p16-positive OPSCC, 2) M0 disease 3) receipt of definitive CRT. Blood 
specimens were collected at baseline, weekly during CRT, and at follow-up visits. Optimized 
multianalyte digital PCR assays were used to quantify ctHPVDNA (types -16/18/31/33/35) in 
plasma. A control cohort of 55 healthy volunteers and 60 patients with non-HPV-associated 
malignancy, was also analyzed.
Results—Baseline plasma ctHPVDNA had high specificity (97%) and high sensitivity (89%) for 
detecting newly diagnosed HPV-associated OPSCC. Pre-treatment ctHPV16DNA copy number 
correlated with disease burden, tumor HPV copy number, and HPV integration status. We define a 
ctHPV16DNA favorable clearance profile as having high baseline copy number (>200 copies/mL) 
and >95% clearance of ctHPV16DNA by day 28 of CRT. Nineteen out of 67 evaluable patients 
had a ctHPV16DNA favorable clearance profile, and none had persistent or recurrent regional 
disease after CRT. In contrast, patients with adverse clinical risk factors (T4 or >10 pack years) 
and an unfavorable ctHPV16DNA clearance profile had a 35% actuarial rate of persistent or 
recurrent regional disease after CRT (p = 0.0049).
Conclusions and Relevance—A rapid clearance profile of ctHPVDNA may predict 
likelihood of disease control in patients with HPV-associated OPSCC patients treated with 
definitive CRT, and may be useful in selecting patients for de-intensified therapy.
Trial Registration—, ,
Keywords
HPV; digital PCR; Oropharyngeal Cancer; Radiation; Phase II
Introduction
The discovery of human papilloma virus (HPV) infection as a driver of oropharyngeal 
carcinogenesis has been a major advancement in head and neck oncology. Patients with 
HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) have a significantly 
better prognosis than patients with HPV-negative OPSCC(1). The three-year local regional 
control and overall survival for HPV-associated vs. HPV negative are respectively: 86% vs. 
65% and 82% vs. 46%(1). Further risk stratification of patients with HPV-associated 
OPSCC is done using tobacco smoking history: low risk (HPV-associated, ≤ 10 pack years, 
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overall survival 93%) and intermediate risk (HPV-associated, >10 pack years, overall 
survival 71%)(1).
It is now standard clinical practice to use HPV, smoking status, and disease stage to risk 
stratify patients to facilitate prognostication, and therapeutic exploration of de-intensified 
treatment regimens is an active area of clinical trial research(2,3). Though the primary 
biomarker of HPV-status and secondary modifier of tobacco pack years (TPY) allow for 
significant prognostication, they are imprecise. For example, >10 TPY did not impact cancer 
control in HPV-associated OPSCC patients in a large retrospective study of 899 patients(4). 
Others have also reported lower tumor HPV copy number, presence of non-HPV16 viral 
strains, and HPV integration as being associated with adverse prognosis(5–12). Thus, there 
is a need to identify additional biomarkers of therapeutic sensitivity that may help to better 
risk stratify patients.
Circulating tumor DNA (ctDNA) is released by dying cancer cells and represents an 
accessible source for detecting tumor genetic biomarkers in many cancer types, including 
OPSCC(13). Plasma ctDNA can be evaluated serially over time to analyze the profile of 
molecular ctDNA responses during cancer therapy(14). The clinical utility of Epstein Barr 
Virus (EBV) ctDNA has been established for the early detection(15) of EBV-associated 
nasopharyngeal cancer and prognostication of patients after definitive chemoradiotherapy 
(CRT)(16). Similarly, plasma circulating tumor HPV16 DNA (ctHPV16DNA) is detectable 
in the majority of patients with HPV-associated OPSCC(12,17–20). Limited prior data has 
shown that ctHPV16DNA levels become largely undetectable post CRT in most patients, 
and that ctHPV16DNA levels may increase at the time of disease recurrence(12,19–21). 
These prior studies retrospectively analyzed limited subsets of patients using real-time PCR.
We have designed and validated a highly sensitive and specific digital PCR (dPCR) assay for 
absolute quantification of circulating tumor HPV16 DNA (ctHPV16DNA), as well as 
circulating tumor HPV DNA for the four most prevalent alternative high-risk HPV strains 
(18/31/33/35). We integrated these ctHPVDNA analyses into our ongoing multi-institutional 
prospective phase II clinical trials for patients with HPV-associated OPSCC, to investigate 
whether ctHPVDNA baseline levels and clearance kinetics improve risk stratification when 
combined with established clinical risk factors. We herein report our observations regarding 
a ctHPV16DNA rapid clearance profile that, in combination with established clinical risk 
factors, predicts local and regional disease control after definitive CRT.
Materials and Methods
Ethics Approval and Consent to Participate
All patients included in this study provided written informed consent to an IRB-approved 
prospective biomarker study at the University of North Carolina at Chapel Hill Cancer 
Hospital that was conducted in accordance with the U.S. Common Rule.
Study Design and Eligibility
Patients with HPV-associated OPSCC were enrolled on an IRB approved (UNC IRB 11–
1924) prospective biomarker study (NCT0316182). All patients provided written informed 
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consent. The major eligibility criteria were: 1) age 18 years age or older, 2) biopsy proven 
squamous cell carcinoma of the oropharynx, 3) p16 positivity (defined as >70% of 
carcinoma cells showing nuclear reactivity), 4) T0 to T4, N0 to N3, M0 (AJCC 7th edition), 
and 5) receiving definitive CRT. Patients with T0 to T3, N0 to N2c (AJCC 7th edition) and 
with a tobacco smoking history of ≤ 10 TPY or >10 TPY and not actively smoking at time 
of diagnosis were co-enrolled on two institutional single arm phase II de-intensified CRT 
trial (NCT02281955 or NCT03077243). Fifty-five healthy volunteers and sixty patients with 
non-HPV-associated malignancy were also enrolled as a control cohort. A REMARK 
diagram of the patient cohorts analyzed in this study is provided in Figure 1.
Definitive Chemoradiotherapy
Patients not co-enrolled on the phase II de-intensification CRT trials received standard of 
care 70Gy intensity modulated radiotherapy (IMRT) with concurrent chemotherapy. All 
patients enrolled on the phase II de-intensification CRT trials received 60Gy IMRT with 
concurrent weekly intravenous cisplatin 30 mg/m2. Patients with T0-T2 N0–1 disease did 
not receive chemotherapy. All patients had a 3 month post-treatment PET/CT and clinical 
examination to determine need for neck dissection. Thereafter, patients underwent clinical 
examinations every 2–4 months for years 1–2, then every 6 months for years 3–5. Chest 
imaging was performed every 6 months.
Blood Collection and Extraction of Circulating DNA
De-identified blood specimens were collected pre-treatment, weekly during CRT, and with 
each post treatment follow-up visit in 10 mL cell-free DNA BCT® blood collection tubes 
(Streck 218962), and double-spun plasma (2000×g) was harvested within 3 days for storage 
at −80°C. for ctHPVDNA analysis. Plasma cell-free DNA (cfDNA) was extracted from 2–5 
ml of plasma using the QIAamp circulating nucleic acid kit (Qiagen, Valencia, CA, USA; 
Catalog No. 55114). The amount of purified cfDNA was quantified with a Qubit® 
fluorometer and PicoGreen quantification reagents (Invitrogen, Carlsbad, CA, USA).
Chemicals and reagents
Droplet digital PCR reagents (2x ddPCR™ Supermix for Probes (No dUTP) Catalog # 186–
3024; Pipet tips Catalog # 186–4121; Cartridge Catalog # 186–4109 and Sealing foil 
Catalog #181–4040) were purchased from Bio-Rad (Hercules, CA). Eppendorf™ 96-Well 
twin.tec™ PCR Plates (Catalog #E951020362), Falcon® 15ml Conical Centrifuge Tubes 
(Catalog # 352096), Falcon™ 50mL Conical Centrifuge Tubes (Corning #352098), Qubit™ 
dsDNA HS Assay Kit (Catalog # Q32851), and Qubit™ Assay Tubes (Catalog # Q32856) 
were purchased from Fisher scientific (Fair Hampton, NH). Bovine Serum Albumin was 
from Sigma (Catalog # A7906; Sigma–Aldrich, St. Louis, MO). Circulating DNA was 
quantified with Qubit (Invitrogen, Carlsbad, CA, USA). Target gene fragments for HPV 
subtype 16, 18, 31, 33, and 35 were synthesized as gBlocks from IDT for use as positive 
controls (Supplementary Table S1). These gBlocks were cloned into a pCR2.1-TOPO TA 
vector by Topo TA cloning kit (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s protocol. The gene fragment constructs were verified by Sanger sequencing 
(Genewiz, New Jersey, USA). FAM-, TET- or HEX-conjugated Locked Nucleic Acids 
(LNA)-modified DNA oligonucleotide probes and FAM-ZEN dual quencher probes were 
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synthesized by IDT (Integrated DNA Technology, San Jose, CA, see Supplementary Table 
S1).
ctHPV16DNA dPCR assay and detection of HPV variants
Primers and 5’ hydrolysis probes were designed to specifically detect a ~75bp amplicon 
within the E7 gene encoded by high-risk HPV strains 16, 18, 31, 33, and 35. Sequence 
details of the primers and probes used in this study are listed in Supplementary Table S1. 
Each reaction assay contained 10 μl of 2x dPCR™ Supermix for Probes (No dUTP), 0.9 μM 
of respective primers, 0.25 μM of respective probes, and 5–50 ng of cfDNA in a final 
volume of 20 μl. Digital droplet PCR assays were performed on the QX100 and/or QX200 
platforms outfitted with an automated droplet generator (Bio-Rad). Each assay was validated 
against control DNA samples comprising either the complete genome for the HPV strain of 
interest, or the relevant portion of the E7 gene. All assays were specific for the HPV strain of 
interest, with no cross-reactivity to all other HPV strains tested. Standardized thresholds for 
positive and negative droplets were used across all samples. A dPCR assay for a control 
locus in the ESR1 gene was used to assess sample quality. All dPCR data was analyzed 
using QuantaSoft software version 1.7.4.0917 (Bio-Rad). Additional details of the dPCR 
assays used in this study are provided in the Supplementary Material.
Analysis of Tumor HPV copy number and integration status
Targeted exon sequencing was conducted after institutional review board (IRB) approval 
through the UNCseq (University of North Carolina, Chapel Hill, NC, http://
www2.cscc.unc.edu/ unchreg/UNCseq, NCT01457196) pipeline, as previously described 
(22,23). In brief, sequencing data are routed through an automated pipeline. This workflow 
uses paired tumor and normal libraries to detect somatic mutations, large and small indels, 
structural variants, and copy number aberrations. Raw sequences are aligned to 
hg19_(hs37d5), supplemented with the HPV16 (NC_001526.2) and HPV 18 (NC_001357.1) 
genomes, using the Burrows-Wheeler Aligner (BWA) ‘mem’ algorithm. The alignments are 
then refined using our Assembly Based ReAlignment (ABRA(24)) procedure. ABRA 
generates a list of structural variants found in target locations, including HPV-human 
fusions, and permits alignment of both junction-containing and junction bridging reads. 
HPV-human chimeric reads were distinguished from non-chimeric HPV alignments, and 
these counts were normalized to the count of non-chimeric human alignments. Alignment 
details from ABRA were integrated with these normalized counts to generate circos plots for 
a subset of samples (25).
Statistical Analyses
Linear regression, t-tests, and survival analyses were performed in Prism 8 (Graphpad) 
software. Regional Disease-Free Survival (RDFS) was estimated using the Kaplan-Meier 
(KM) method. Regional Disease-Free Survival was measured from the time of the first dose 
of CRT and was defined as time to detection/development of persistent/recurrent disease in 
cervical lymph nodes. Two-sided log-rank test was applied to compare RDFS of different 
subgroups.
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Between 2/2016 and 08/2018, 103 patients were enrolled. The clinical characteristics of the 
study population are shown in Table 1 and a REMARK diagram of cohorts for study 
analyses is presented in Figure 1. A total of 87 patients (84%) received de-intensified CRT 
on clinical trial (60 Gy). The majority of patients were never smokers or had ≤10 pack years 
of tobacco use (75%). HPV status was unknown in 48% (all tumors were p16 positive).
Cancer Control Outcomes
The median follow-up (f/u) for 67 patient subset for whom weekly blood samples were 
collected and a post-treatment PET scan was available was 16.5 months (range 3.9 – 32.9). 
Ten patients had a neck dissection because of incomplete radiographic response on the 3 
month post-treatment PET/CT. Five of 10 patients had a positive neck dissection specimen. 
Three patients had recurrent disease: 0 local, 2 regional and distant, and 1 distant only. The 
actuarial 1-year local control, regional control, and distant metastasis free survival, and OS 
were 100%, 91%, 94%, and 98%, respectively. Actuarial 1-year estimate of RDFS (5 
positive neck dissection specimens and 2 regional recurrences) was 91%.
Plasma circulating tumor HPVDNA is detectable in a majority of oropharyngeal cancer 
patients
A digital PCR (dPCR) assay was developed to amplify and quantify a 73bp region of the 
HPV16 E7 gene. The assay does not cross-detect other HPV subtypes including 
HPV-6/11/18/31/33/35 (Supplementary Figure S1A). A titration analysis reveals exceptional 
linearity (R2 = 0.99) and low variance over 5 orders of magnitude (Supplementary Figure 
S1B).
ctHPV16DNA was undetectable in 52 out of 55 healthy volunteers (Figure 2A). Three 
female volunteers, ages 20, 21, and 31, had low but detectable levels of ctHPV16DNA. We 
were unable to access the clinical history of these healthy volunteers to establish cervical 
HPV status. ctHPV16DNA was not detected in plasma DNA extracted from 60 patients with 
non-HPV associated malignancy (Figure 2A). Eighty four out of 103 (82%) patients with 
HPV-associated OPSCC had detectable pre-treatment ctHPV16DNA (Figure 2B), and 
median copy number 419 copies/mL plasma (range 8 – 22,579). The 19 samples with 
undetectable ctHPV16DNA were also analyzed by specific dPCR assays for alternative 
high-risk HPV strains (HPV 18/31/33/35, Supplementary Figure S2). Eight out of 19 
patients with undetectable baseline ctHPV16DNA were positive for ctHPVDNA from an 
alternative high-risk HPV strain (one HPV31, three HPV33, and four HPV35), with median 
copy number of 124 copies/mL (range 71 – 15,829). Four of the remaining 11 patients who 
were negative for ctHPVDNA for all high-risk strains tested were analyzed by tumor 
genomic sequencing, and two were found to have a TP53 mutation. Based on the analysis of 
103 cases and 115 controls, we estimate that ctHPVDNA testing using an optimized 
multianalyte dPCR assay has 97% specificity and 89% sensitivity to identify patients with 
newly diagnosed and non-metastatic HPV-associated OPSCC.
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Baseline ctHPV16DNA levels correlate with tumor burden and clinical risk factors
There was a trend towards higher baseline plasma ctHPV16DNA levels in patients with T2 
tumors compared to T0/T1 tumors (Figure 2B). Despite having a relatively low number of 
T3/T4 tumors in the cohort, these patients had significantly lower baseline levels of 
ctHPV16DNA relative to patients with T2 tumors (Figure 2B), suggesting that larger tumor 
size may be associated with lower rates of ctHPVDNA release. Consistent with a prior study 
(12), we observed significantly higher ctHPV16DNA levels in patients with N2a/N2b versus 
N0/N1 disease (AJCC 7th edition) (Figure 2C). Again, there was a trend towards lower 
baseline ctHPV16DNA in patients presenting with N2c disease, relative to the N2a/N2b 
patient subgroup (Figure 2C). Similar trends were seen when AJCC 8th edition N stage 
classifications were used (Supplementary Figure S3). These findings suggest that tumor 
burden alone may not explain the variable levels of pre-treatment ctHPV16DNA in OPSCC 
patients. Notably, patients with adverse clinical risk factors (> 10 TPY or T4) had lower 
baseline ctHPV16DNA levels than patients with low clinical risk (≤10 TPY and <T4) 
(Figure 2D). Thus, although ctHPV16DNA is detectable in a majority of patients with newly 
diagnosed HPV-associated OPSCC, low baseline and undetectable ctHPV16DNA levels may 
be associated with clinically higher-risk disease.
Rapid clearance kinetics of ctHPV16DNA during CRT in a subset of patients
We next investigated kinetics of ctHPV16DNA clearance during CRT in a subset of 67 
patients for whom weekly blood samples were collected and a post-treatment PET scan 
result was available to assess treatment response (median follow-up 16.5 months). Fifty-four 
out of 67 patients had detectable baseline ctHPV16DNA. In 35 out of 54 patients (65%), 
ctHPV16DNA levels increased after initiating CRT before diminishing later in the course of 
therapy (Figure 3A). Patients with ≤200 copies/mL of baseline ctHPV16DNA had labile 
clearance kinetics (Supplementary Figure S4), possibly due to a lower reliability of signal 
detection or non-uniform responses to treatment. Thus, we analyzed weekly ctHPV16DNA 
clearance kinetics in the 40 patient subset (out of 67) who had >200 copies/mL baseline 
ctHPV16DNA. Levels of ctHPV16DNA diminished during CRT, and approximately 80% of 
patients had eliminated all ctHPV16DNA by the end of CRT (Figure 3B). Furthermore, 
ctHPV16DNA had cleared in 92%, 94%, and 100% of patients by 6 months, 1 year, and 2 
years post-CRT, respectively. Patients with detectable ctHPV16DNA at the end of week 6 of 
CRT did not have a higher incidence of residual or recurrent disease (Supplementary Figure 
S5). Alternatively, we measured percent clearance of ctHPV16DNA at week 4 relative to 
pre-treatment levels as a potential indicator of CRT sensitivity, as has previously been 
investigated for EBV-associated nasopharyngeal cancer(26). Using a median cutoff of >95% 
clearance at week 4 (day 25–31), we identified 19 patients with a ctHPV16DNA rapid 
clearance profile (Figure 3C). These patients had a consistent drop in ctHPV16DNA during 
CRT, and all patients had a clinical complete response to CRT. In contrast, the remaining 21 
patients had delayed clearance kinetics (</= 95% clearance at week 4), exhibited more 
unpredictable ctHPV16DNA profiles (Figure 3D), and 3 of these patients had persistence/
recurrent disease after CRT (2 positive neck dissections, 1 distant metastasis). Thus, 
ctHPV16DNA rapid clearance kinetics, defined as >95% clearance by week 4, may be a 
biomarker of CRT sensitivity and greater likelihood of disease control.
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Low baseline ctHPV16DNA levels correlates with low tumor HPV copy number and HPV 
integration
Twenty HPV16 positive patients in our cohort were co-enrolled on an institutional cancer 
genomic registry study (NCT01457196) and underwent next-generation sequencing (NGS) 
of their diagnostic tissue biopsy using the UNCSeq platform (27), as well as quantification 
of HPVDNA using dPCR. We observed excellent correlation between HPV16 copies per 
haploid genome measured by dPCR and HPV16 read counts per 106 total aligned reads by 
NGS (Figure 4A). Patients with low baseline ctHPV16DNA (</= 200 copies/mL) had a 
significantly lower tumor HPV copy number than patients with high baseline ctHPV16DNA 
(>200 copies/mL) (Figure 4B). We next evaluated HPV structure in tumors using a validated 
insertion-deletion detection algorithm(24) to quantify HPV-chromosomal fusion reads that 
are indicative of HPV integration into the somatic genome (Figure 4C). As a positive 
control, we detected end-to-start fusions of the HPV genome (“HPV-HPV fusion”) in all 
samples, which is expected because the HPV reference genome is deposited as a linear 
sequence yet originates as a circular episome in nature. There was evidence for HPV 
integration in 8 out of 20 patients (40%, Figure 4C). Circos plots are shown for two 
representative tumors without and with HPV integration (Figure 4D). A significantly higher 
proportion of patients with low tumor HPV copy number (≤5 copies/haploid genome) had 
HPV integration (Figure 4E, p=0.02). Similarly, patients with low baseline ctHPV16DNA 
(≤200 copies/mL) were more likely to have HPV integration (Figure 4F, p=0.11). Thus, low 
baseline levels of ctHPV16DNA are indicative of lower tumor HPV copy number and a 
greater likelihood of HPV integration, both of which represent adverse tumor genomic 
features.
ctHPV16DNA rapid clearance profile and correlation to local and regional disease control
We next analyzed correlation between ctHPV16DNA clearance profile and disease control in 
the same 67 patient subset with available weekly blood samples, post-treatment PET scans, 
and subsequent clinical follow-up (median 16.5 months). We defined a favorable 
ctHPV16DNA clearance profile as high baseline level (>200 copies/mL) with rapid 
clearance (>95% clearance by week 4). Twenty-eight percent of the patient cohort (19/67) 
had a favorable ctHPV16DNA clearance profile, which did not differ based on established 
clinical risk factors (Figure 5A). The remaining patients had an unfavorable ctHPV16DNA 
profile (undetectable or ≤200 copies/mL at baseline, or ≤ 95% clearance by week 4). 
Patients with an unfavorable ctHPV16DNA clearance profile had a higher frequency of 
regional disease persistence/recurrence and distant metastasis, particularly amongst the 
clinical high-risk patient subset (Figure 5B). We next quantified actuarial persistent/recurrent 
regional disease-free survival (RDFS) after CRT. Patients with a favorable ctHPV16DNA 
clearance profile had 100% RDFS (Figure 5C). Among patients with an unfavorable 
ctHPV16DNA clearance profile, there was an interaction with established clinical risk 
factors. Patients with clinical low-risk disease (≤10 TPY and <T4) had ~90% RDFS, 
whereas patients with clinical high-risk disease (>10 TPY or T4) had ~65% RDFS at 18 
months post-CRT (Figure 5C, p = 0.0049). These findings suggest that favorable 
ctHPV16DNA clearance profile identifies a low-risk subset of HPV-associated OPSCC 
patients (possibly regardless of clinical risk factors) that are highly responsive to definitive 
CRT.
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We have prospectively analyzed ctHPVDNA baseline levels and clearance kinetics in a 
cohort of newly diagnosed HPV-associated OPSCC patients treated with definitive CRT, 
84% of whom were treated with de-intensified CRT on a multi-institutional phase II study. 
Our findings add to a growing body of evidence that ctHPVDNA is a promising biomarker 
for early detection of HPV-associated OPSCC (sensitivity 89% and specificity 97%), similar 
to the utility of ctEBVDNA in screening programs for EBV-associated nasopharyngeal 
cancer(15). Significantly, 11% of our cohort had undetectable ctHPVDNA from 5 of the 
most common HPV strains that have been linked to OPSCC, suggesting that some of these 
cases may represent false positives due to p16-based identification, consistent with another 
recent report(28).
Although baseline ctHPVDNA copy number correlated with disease burden, we observed 
paradoxically lower plasma ctHPVDNA levels in patients with adverse clinical risk factors 
(Figure 2D, >10 TPY or T4 disease). By analyzing matched tumor genomics, we discovered 
that patients with low pre-treatment ctHPV16DNA levels (≤ 200 copies/mL) had lower 
tumor HPV copy number and a higher likelihood of HPV integration, which are associated 
with worse outcomes in OPSCC(5,6,8–12,29). In contrast, patients with abundant pre-
treatment ctHPV16DNA levels (>200 copies/mL plasma) were most likely to have tumors 
with high copy and episomal HPV, which correlates with favorable prognosis in both 
cervical cancer and OPSCC(8,9,11,14). Thus, beyond simply a measure of tumor burden, 
high baseline plasma ctHPV16DNA levels (>200 copies/mL) are indicative of favorable 
tumor genomic biomarkers.
We also found that the rate of ctHPV16DNA clearance correlates with CRT sensitivity. 
Using week 4 of CRT as a benchmark timepoint, we defined a favorable ctHPV16DNA 
clearance profile as elevated baseline levels (>200 copies/mL) that are rapidly cleared 
(>95% clearance of pre-treatment levels by week 4). Patients with a favorable ctHPV16DNA 
clearance profile had excellent RDFS (~100% at 18 months). Amongst patients with an 
unfavorable ctHPV16DNA clearance profile, those with adverse clinical risk factors (>10 
TPY or T4) experienced a high rate of residual or recurrent regional nodal disease (~35% at 
18 months), which resembles disease control rates after CRT for HPV negative OPSCC.
Although there are parallels between ctHPVDNA in OPSCC and ctEBVDNA in NPC with 
regards to early detection, our findings highlight a few clinically significant differences as 
well. First, whereas high pre-treatment levels of ctEBVDNA are associated with worse 
prognosis in NPC(16), we find that the opposite is true for ctHPVDNA in OPSCC (i.e., low 
pre-treatment ctHPVDNA levels are associated with worse clinical outcomes). Second, a 
recent study demonstrated the prognostic significance of ctEBVDNA at the end of CRT as 
predictive of NPC recurrence(30). We did not observe a similar correlation with 
ctHPVDNA, as patients with detectable signal at the end of CRT were not enriched for those 
that later developed residual or recurrent disease. However, a high ctHPVDNA clearance 
percentage at week 4 (i.e., >95%) was associated with a lower rate of regional disease 
persistence/recurrence, similar to what has been shown in EBV-associated NPC(26). A 
possible explanation for these discrepant findings may be due to the highly variable HPV 
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copy numbers per tumor genome that are observed in HPV-associated OPSCC (see Figure 
4A–B). Tumors with high-copy, episomal HPV may have as many as 50–100 copies per cell, 
which may make it possible to detect small amounts of residual ctHPVDNA even when CRT 
has effectively treated all of the active disease. Thus, the specific ctDNA profiles associated 
with clinical outcomes may differ according to the distinct clinical and biological features of 
EBV-associated NPC and HPV-associated OPSCC, respectively.
The potential clinical utility of ctHPV16DNA monitoring in OPSCC is broad, especially in 
light of recent evidence that some forms of de-intensified therapy are not effective for all 
patients with HPV-associated OPSCC(31,32). Future studies should prospectively 
investigate whether ctHPVDNA kinetics can dynamically guide in “real-time” the intensity 
of CRT that may be required. Can patients with ≤ 10 TPY and a favorable ctHPV16DNA 
profile be further de-escalated (reduce radiation to 50 or 54Gy)? Is de-intensified CRT 
efficacious in patients with >10 TPY and a favorable ctHPV16DNA profile? Our data 
suggests that de-intensified CRT should not be offered to patients with an unfavorable 
ctHPVDNA profile and >10 TPY or T4 disease. Our findings illustrate that dynamic 
monitoring of ctHPVDNA during CRT may facilitate personalized treatment decisions to 
maximize tumor control while also minimizing treatment-associated morbidity.
Another potential clinical utility of dynamic ctHPVDNA monitoring may be in the post-
treatment, surveillance setting. Our findings indicate that the sensitivity of ctHPVDNA 
appears to be quite high, and its use to detect cancer recurrence after definitive treatment 
may be advantageous. ctHPVDNA based surveillance may detect recurrences earlier than 
standard clinical visits and occasional radiographic surveillance. Early detection may result 
in a greater occurrence of the oligometastatic state and thus allow for more aggressive 
salvage treatment (e.g. metastasectomy, radiosurgery) that may have greater efficacy. 
Furthermore, ctHPVDNA surveillance may be more cost effective than current surveillance 
approaches.
Limitations
Although our trial included over 100 patients, it is underpowered due to low occurrence of 
disease persistence/recurrence and limited follow-up. Despite these limitations, we observed 
an early trend in worse RDFS (Figure 5C) in patients with >10 TPY and unfavorable 
ctHPVDNA kinetics. Validation of our findings using a clinical-grade test in independent 
and larger patient cohorts will be necessary to confirm our findings.
Conclusions and Future Directions
Circulating tumor HPVDNA is present in most patients with newly diagnosed HPV-
associated OPSCC. Our findings suggest that a rapid clearance profile of ctHPV16DNA 
clearance during CRT may have clinical utility in stratifying patients with HPV-associated 
OPSCC based on likelihood of disease control. Future studies assessing ctHPVDNA as an 
integral biomarker to guide treatment de-intensification are warranted, and may facilitate 
personalized treatment decisions based on tumor biology in addition to clinical risk factors. 
Finally, prospective evaluation of ctHPVDNA as a biomarker in other HPV-associated 
malignancies (e.g. cervical and anal cancers) should be evaluated.
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Plasma circulating tumor HPV DNA (ctHPVDNA) is a promising biomarker for 
monitoring treatment responses in patients with HPV-associated oropharyngeal squamous 
cell carcinoma (OPSCC). This study characterizes baseline levels and clearance kinetics 
of ctHPVDNA in a cohort of patients treated with definitive chemoradiotherapy (CRT). A 
favorable clearance profile was defined as high baseline ctHPVDNA levels (>200 
copies/mL) that are rapidly eliminated during CRT (>95% clearance by day 28). Patients 
with a favorable clearance profile, regardless of tobacco pack years, had excellent cancer 
control (Regional DFS = 100%), while those with unfavorable clearance profile and 
adverse clinical factors (T4, > 10 tobacco pack years) had significantly worse cancer 
control (Regional DFS = 65%). Future studies assessing ctHPVDNA as an integral 
biomarker to guide treatment de-intensification are warranted, and may facilitate 
personalized treatment decisions based on tumor biology in addition to clinical risk 
factors.
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REMARK diagram of patient cohorts analyzed in this study.
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Figure 2. Detection of plasma ctHPVDNA in HPV-associated oropharyngeal cancer patients.
(A) Measurement of ctHPVDNA copies/mL plasma in 55 healthy volunteers, 60 patients 
with non-HPV associated cancers, and 103 patients with HPV-associated OPSCC. Two-
toned (red-black) circles denote patients who were negative for ctHPV16DNA but positive 
for ctHPVDNA from an alternative high-risk HPV strain (-18/31/33/35). (B-D) Baseline 
levels of ctHPV16DNA stratified by (B) tumor stage, (C) nodal stage, and (D) clinical risk 
factors. Median and inter-quartile range is shown for each graph. *, p<0.05; p-values based 
on a two-sided Mann-Whitney test.
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Figure 3. Variable kinetics of ctHPV16DNA clearance during chemoradiotherapy.
(A) Normalized ctHPV16DNA abundance (relative to the highest measured value for each 
patient) at baseline, peak value between week 1–3 of CRT, and nadir after treatment (within 
6 months of completing therapy) for 54 evaluable patients with detectable ctHPV16DNA. In 
one subgroup (red lines, N = 19) ctHPV16DNA levels decrease immediately after initiating 
CRT, whereas in the second subgroup (blue lines, N = 35) ctHPV16DNA levels initially 
spike followed by a subsequent decrease. (B) Percentage of patients with ctHPV16DNA 
elimination at different time points after initiating CRT. (C) Percentage clearance of 
ctHPV16DNA at week 4 in 40 patients with baseline ctHPV16DNA levels >200 copies/mL. 
Red dots indicate patients that later developed residual or recurrent disease. (D) Rapid 
ctHPV16DNA clearance kinetics in patients with >95% clearance of baseline ctHPV16DNA 
levels by week 4 of CRT. (E) Delayed ctHPV16DNA clearance kinetics in patients with 95% 
or less clearance of baseline ctHPV16DNA levels by week 4 of CRT.
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Figure 4. Correlation between ctHPV16DNA and tumor HPV genomic features.
(A) Spearman correlation between copies of HPV16 detected in tumor biopsy samples by 
dPCR and NGS (B) Tumor HPV16 copies per genome equivalent (GE) in patients grouped 
by baseline ctHPV16DNA levels. Mean ± SEM is shown. P value calculated using a two-
tailed, unpaired t-test with unequal variances. (C) Normalized NGS counts for hybrid HPV-
chromosomal reads (indicative of HPV integration) relative to HPV-HPV fusion reads 
(positive control). (D) Circos plots illustrating the detecting HPV and chromosomal 
rearrangements in a tumor with purely episomal HPV (left panel) and HPV integration into a 
locus on chromosome 8 (right panel). (E-F) Number of tumor samples with integrated versus 
episomal HPV after grouping patients by (E) tumor HPV copy number (per GE) or (F) 
baseline ctHPV16DNA (copies/mL). P values calculated by a two-tailed Fisher’s exact test.
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Figure 5. A favorable ctHPV16DNA clearance profile correlates with disease control in OPSCC 
patients treated with CRT.
(A) Percentages of clinical low-risk and clinical high-risk patients with a favorable 
ctHPV16DNA profile, which is defined as baseline ctHPV16DNA >200 copies/mL and 
>95% clearance by week 4. (B) Percentage of patients within each subgroup who experience 
a positive neck dissection, regional recurrence, or distant metastasis. (C) Kaplan-Meier 
analysis of regional disease-free survival stratified by clinical risk and ctHPV16DNA profile. 
P value calculated using a two-tailed log-rank test for trend.
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